Table 1.

Case series and retrospective studies of progestins in the setting of recurrent, metastatic, or unresectable LGESS

Study (y)	n	Age	Hormonal treatment	Response	Duration (mo)
Chu (2003)56	8	–	progestins	4 CR, 3 SD, 1 PD	18‐180
Pink (2006)22	3	42‐63	MPA	1 CR, 1 SD, 1 PD	0‐50
Dahhan (2009)57	8	27‐46	MA	4 CR, 3 PR, 1 SD	18‐252
Ioffe (2009)49	5	–	MA, MPA	1 PR, 3 SD, 1 PD	6‐124
Mizuno (2012)58	6	32‐53	MPA	3 PR, 3 SD	26‐146
Yamazaki (2015)28	8	50‐69	MPA	3 CR, 2 PR, 1 SD, 2 PD	–
Total	38		progestins	12 CR (31.6%), 9 PR (23.7%), 12 SD (31.6%), 5 PD (13.2%) Effective rate: 86.9%

CR, complete response; MA, megestrol acetate; MPA, medroxyprogesterone acetate; PD, progression of disease; PR, partial response; SD, stable disease; —, the data were not described clearly.

Effective rate: CR+PR+SD.